Tubulis achieves key milestone in BMS deal

German antibody drug conjugate (ADC) specialist Tubulis announced that the first program from its 2023 licensing accord with pharma major Bristol Myers Squibb (NYSE: BMY) has entered clinical development, triggering a significant milestone in the ongoing collaboration to develop next generation antibody drug candidates (ADCs) for the treatment of cancer.

The agreement was established to combine BMS’ deep oncology and clinical development expertise and Tubulis’ differentiated and unique approach to ADC design for the development of a selected number of highly differentiated ADCs to treat solid tumors.

“Within two years, this collaboration has advanced an exciting ADC candidate into the clinic, and we remain highly committed to this robust and valuable partnership,” said Dominik Schumacher, chief executive and co-founder of Tubulis. “Having brought three Tubutecan-based ADC candidates into the clinic within just 12 months, including our wholly owned programs TUB-030 and TUB-040, we are continuing to demonstrate the versatility and translational potential of our technologies in delivering more effective cancer therapeutics,” he added.